Summit Therapeutics share price today
(NASDAQ: SMMT)

Name: Summit Therapeutics Share Price Today (NASDAQ: SMMT) - Summit Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Summit Therapeutics share price is $24.65 & ₹2,131.98 as on 24 Jan 2025, 2.30 'hrs' IST

$24.65

▲

1.13

(4.8%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Summit Therapeutics share price in Dollar and Rupees. Guide to invest in Summit Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Summit Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Summit Therapeutics share price movements

Today's Low: $23.02
Today's High: $24.99
$24.65
6.61%
Downside
Day's Volatility :7.88%
Upside
1.36%
52 Weeks Low: $2.10
52 Weeks High: $33.89
$24.65
91.48%
Downside
52 Weeks Volatility :93.8%
Upside
27.26%

Summit Therapeutics Returns

Period	Summit Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	10.63%	-5.5%	0.0%
6 Months	103.64%	-4.3%	0.0%
1 Year	416.92%	1.6%	0.0%
3 Years	1030.77%	9.8%	-11.0%

Summit Therapeutics Key Statistics

in dollars & INR

Previous Close	$23.52
Open	$22.96
Today's High	$24.99
Today's Low	$23.02
Market Capitalization	$16.3B
Today's Volume	$4.4M
52 Week High	$33.89
52 Week Low	$2.1
Revenue TTM	$0.0
EBITDA	$-181.5M
Earnings Per Share (EPS)	$-0.23
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-73.21%

How to invest in Summit Therapeutics Stock (SMMT) from India?

It is very easy for Indian residents to invest directly in Summit Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Summit Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Summit Therapeutics or SMMT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Summit Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Summit Therapeutics shares which would translate to 0.035 fractional shares of Summit Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Summit Therapeutics, in just a few clicks!

Returns in Summit Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Summit Therapeutics investment value today

Current value as on today

₹5,45,813

Returns

₹4,45,813

(+445.81%)

Returns from Summit Therapeutics Stock

₹4,41,758 (+441.76%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Summit Therapeutics

-28.57%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Investment in Summit Therapeutics from India has reduced in the last 30 days as on Jan 24, 2025. -28.57% less purchase transactions for Summit Therapeutics in the last 30 days versus the previous period.

-48%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Summit Therapeutics on INDmoney from India has reduced in the last 30 days as on Jan 24, 2025. -48% less investors are searching Summit Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Summit Therapeutics

Baker Bros Advisors LP
3.31%
Vanguard Group Inc
1.48%
FMR Inc
1.13%
BlackRock Inc
1.10%
T. Rowe Price Associates, Inc.
0.74%
State Street Corp
0.47%

Analyst Recommendation on Summit Therapeutics

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Summit Therapeutics(by analysts ranked 0 to 5 stars)

Based on 7 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Summit Therapeutics

What analysts predicted

Upside of 34.24%

Target:

$33.09

Current:

$24.65

Insights on Summit Therapeutics

Price Movement
In the last 7 days, SMMT stock has moved up by 29.3%
Decreasing Revenue
Revenue is down for the last 3 quarters, 235.0K → -235.0K (in $), with an average decrease of 100.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -60.38M → -56.25M (in $), with an average increase of 7.3% per quarter

Summit Therapeutics Technicals Summary

Sell

Neutral

Buy

Summit Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Summit Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Summit Therapeutics Inc	23.79%	103.64%	416.92%	1030.77%	583.72%
Biontech Se	0.91%	34.01%	18.85%	-26.4%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.95%	-28.33%	12.74%	100.35%
Vertex Pharmaceuticals Incorporated	4.86%	-13.58%	-0.46%	88.45%	88.24%
Alnylam Pharmaceuticals, Inc.	9.57%	13.5%	44.91%	103.56%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Summit Therapeutics Inc	26.36	NA	0.0	-0.24	-0.73	-0.31	NA	0.59
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Summit Therapeutics Inc	Buy	$16.3B	583.72%	26.36	0.0%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Organization	Summit Therapeutics
Employees	105
CEO	Mr. Robert W. Duggan
Industry	Health Technology

Management People of Summit Therapeutics

Name	Title
Mr. Robert W. Duggan	Co-CEO & Executive Chairman
Dr. Mahkam Zanganeh D.D.S., M.B.A.	Co-CEO, President & Director
Mr. Manmeet Singh Soni CPA	COO, CFO & Director
Prof. Dame Kay Davies DBE, FRS CBE	Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
Mr. Bhaskar Anand	Chief Accounting Officer & Head of Finance
Ms. Divya Chari	Head of Global Clinical Operations
Mr. Dave Gancarz	Chief Business & Strategy Officer
Dr. Betty Y. Chang Ph.D.	Head of Research, Oncology & Inflammation
Dr. Fong Clow	Chief Biometrics Officer
Ms. Shelley D. Spray	Chief Education & Brand Officer

Important FAQs about investing in Summit Therapeutics (SMMT) from India :

What is Summit Therapeutics share price today?

Summit Therapeutics share price today stands at $24.65, Open: $22.96 ; Previous Close: $23.52 ; High: $24.99 ; Low: $23.02 ; 52 Week High: $33.89 ; 52 Week Low: $2.10. The stock opens at $22.96, after a previous close of $23.52. The stock reached a daily high of $24.99 and a low of $23.02, with a 52-week high of $33.89 and a 52-week low of $2.10.

Can Indians buy Summit Therapeutics shares?

Yes, Indians can invest in the Summit Therapeutics (SMMT) from India.

With INDmoney, you can buy Summit Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Summit Therapeutics at zero transaction cost.

How can I buy Summit Therapeutics shares from India?

It is very easy to buy Summit Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Summit Therapeutics be purchased?

Yes, you can buy fractional shares of Summit Therapeutics with INDmoney app.

What are the documents required to start investing in Summit Therapeutics stocks?

To start investing in Summit Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.